Exploiting Pseudomonas putida for drug development.
In this issue of Chemistry & Biology, a strategy that combines large DNA fragment recombineering in Escherichia coli and heterologous expression in Pseudomonas putida is described. The work focuses on myxochromide S, a natural compound produced by Stigmatella aurantiaca.
Bechthold
Andreas
A
Albert-Ludwigs-Universität Freiburg im Breisgau, Institut für Pharmazeutische Biologie und Biotechnologie, Freiburg, Germany.
D004274:DNA, Recombinant / Q000096:biosynthesis / Q000235:genetics; D015195:Drug Design; D005813:Genes, Synthetic; D005818:Genetic Engineering / Q000379:methods* / Q000639:trends*; D020560:Proteobacteria / Q000737:chemistry / Q000235:genetics; D016958:Pseudomonas putida / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism
D004274:DNA, Recombinant